InflaRx Announces Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
Portfolio Pulse from Benzinga Newsdesk
InflaRx N.V. (NASDAQ:IFRX) announced topline results from the single ascending dose (SAD) part of its Phase I trial of the orally administered C5aR inhibitor INF904. The results showed an excellent safety and tolerability profile, as well as a favorable pharmacokinetic and pharmacodynamic profile, confirming INF904's best-in-class potential.
September 11, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InflaRx's positive Phase I trial results for INF904 could potentially boost the company's stock in the short term.
The announcement of positive Phase I trial results is typically seen as a positive development for biotech companies, as it indicates progress in the drug development process. This could potentially lead to increased investor confidence in InflaRx, which could in turn boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100